Pilot Study to Evaluate a Noninvasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorders Following TAVI Implantation (IMPROVE Study) (IMPROVE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Bruno García del Blanco, MD, PhD
- Phone Number: 00342746155
- Email: bruno.garcia@vallhebron.cat
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Unniversitari Vall d'Hebron
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All inclusion criteria must be met
- Age ≥ 18 years and
- Undergone successful transfemoral or transaortic TAVI for severe aortic stenosis and
- Presence of at least one of the following conduction disorders and
- Pre-procedural basal conduction disorder (e.g., right/left bundle branch block, bifascicular block, IVCD) with QRS between 120-160 msec.
- De novo conduction disorder after TAVI (de novo bundle branch block) with QRS between 120-160 msec.
- Clinical stability at 24 hours post-procedure and
- Capacity to give informed consent.
Exclusion Criteria:
No exclusion criteria must be met
- Immediate indication for permanent pacemaker following the procedure.
- Persistent complete atrioventricular block.
- QRS >160 msec and/or PR prolongation.
- Haemodynamic instability or complications of TAVI (major bleeding, stroke, decompensated heart failure) that contraindicate early discharge.
- Technical or clinical impossibility of using the PhysioMem PM 1004G monitoring system.
- Life expectancy < 12 months due to non-cardiovascular comorbidity.
- Refusal or inability to undergo outpatient follow-up.
- Pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Early discharge (24 hours post-TAVI)
Patients will be discharged from the hospital 24 hours post-TAVI with PhysioMem PM 100 4G ambulatory monitoring system.
|
Patients discharged with PhysioMem PM 100 4G ambulatory monitoring system
|
|
Active Comparator: Discharge according Standard Care
Patients will be discharged from the hospital according standard care
|
Patients discharged according to standard care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite of all-cause death and rehospitalization for any reason
Time Frame: 30 days
|
Proportion of patients with:
|
30 days
|
|
Clinically relevant arrhythmic event requiring a change in therapy
Time Frame: 30 days
|
Proportion of patients with clinically relevant arrhythmic event requiring a change in therapy, defined as the occurrence of any of the following:
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause death
Time Frame: 30 days
|
Incidence of all-cause death
|
30 days
|
|
All-cause death
Time Frame: 12 months
|
Incidence of all-cause death
|
12 months
|
|
Unscheduled hospital readmission for any reason
Time Frame: 30 days
|
Incidence of unscheduled hospital readmission for any reason
|
30 days
|
|
Unscheduled hospital readmission for any reason
Time Frame: 12 months
|
Incidence of unscheduled hospital readmission for any reason
|
12 months
|
|
Cardiovascular death
Time Frame: 30 days
|
Incidence of cardiovascular death
|
30 days
|
|
Cardiovascular death
Time Frame: 12 months
|
Incidence of cardiovascular death
|
12 months
|
|
Hospital readmission due to cardiovascular cause
Time Frame: 30 days
|
Incidence of Hospital readmission due to cardiovascular cause
|
30 days
|
|
Hospital readmission due to cardiovascular cause
Time Frame: 12 months
|
Incidence of Hospital readmission due to cardiovascular cause
|
12 months
|
|
Implantation of a permanent pacemaker
Time Frame: 30 days
|
Incidence of Implantation of a permanent pacemaker
|
30 days
|
|
Implantation of a permanent pacemaker
Time Frame: 12 months
|
Incidence of Implantation of a permanent pacemaker
|
12 months
|
|
High-degree atrioventricular block (II or III)
Time Frame: 30 days
|
Incidence of High-degree atrioventricular block (II or III)
|
30 days
|
|
De novo or recurrent atrial fibrillation requiring a change in therapy
Time Frame: 30 days
|
Incidence of De novo or recurrent atrial fibrillation requiring a change in therapy
|
30 days
|
|
Time to pacemaker implantation or therapeutic change due to arrhythmia
Time Frame: 30 days
|
Incidence of Time to pacemaker implantation or therapeutic change due to arrhythmia
|
30 days
|
|
Time to pacemaker implantation or therapeutic change due to arrhythmia
Time Frame: 12 months
|
Incidence of Time to pacemaker implantation or therapeutic change due to arrhythmia
|
12 months
|
|
Resolution vs persistence of conduction disorders
Time Frame: 72 hours
|
Incidence of Resolution vs persistence of conduction disorders detected in the first 72 hours after TAVI implantation
|
72 hours
|
|
QRS evolution: transient, persistent, or normalisation
Time Frame: 30 days
|
Incidence of QRS evolution: transient, persistent, or normalisation
|
30 days
|
|
Remote monitoring
Time Frame: 30 days
|
Percentage of time monitored correctly
|
30 days
|
|
hospital length to of stay from TAVI to discharge
Time Frame: At discharge
|
Duration of hospitalization post-TAVI procedure
|
At discharge
|
|
Direct cost associated with stay and readmissions
Time Frame: 12 Months
|
Evaluation of Direct cost associated with hospital stay and readmissions
|
12 Months
|
|
Quality of life assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: 30 days
|
Quality of life assessed using (KCCQ)assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ).
The KCCQ is a 23-item questionnaire developed to assess HRQoL (Health-Related Quality of Life) in patients with congestive heart failure.
The KCCQ consists of five domains: physical limitation, symptoms (frequency, severity, and recent change over time), QoL (Quality of Life), social interference, and self-efficacy.
The total score ranges from 0 to 100, and higher scores reflect better health status.
|
30 days
|
|
Quality of life assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: 12 Months
|
Quality of life assessed using (KCCQ)assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ).
The KCCQ is a 23-item questionnaire developed to assess HRQoL (Health-Related Quality of Life) in patients with congestive heart failure.
The KCCQ consists of five domains: physical limitation, symptoms (frequency, severity, and recent change over time), QoL (Quality of Life), social interference, and self-efficacy.
The total score ranges from 0 to 100, and higher scores reflect better health status.
|
12 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Piazza N, Nuis RJ, Tzikas A, Otten A, Onuma Y, Garcia-Garcia H, Schultz C, van Domburg R, van Es GA, van Geuns R, de Jaegere P, Serruys PW. Persistent conduction abnormalities and requirements for pacemaking six months after transcatheter aortic valve implantation. EuroIntervention. 2010 Sep;6(4):475-84. doi: 10.4244/EIJ30V6I4A80.
- van Gils L, Baart S, Kroon H, Rahhab Z, El Faquir N, Rodriguez Olivares R, Aga Y, Maugenest AM, Theuns DA, Boersma E, Szili Torok T, De Jaegere PP, Van Mieghem NM. Conduction dynamics after transcatheter aortic valve implantation and implications for permanent pacemaker implantation and early discharge: the CONDUCT-study. Europace. 2018 Dec 1;20(12):1981-1988. doi: 10.1093/europace/euy074.
- Szotek M, Druzbicki L, Sabatowski K, Amoroso GR, De Schouwer K, Matusik PT. Transcatheter Aortic Valve Implantation and Cardiac Conduction Abnormalities: Prevalence, Risk Factors and Management. J Clin Med. 2023 Sep 19;12(18):6056. doi: 10.3390/jcm12186056.
- Mangieri A, Montalto C, Pagnesi M, Lanzillo G, Demir O, Testa L, Colombo A, Latib A. TAVI and Post Procedural Cardiac Conduction Abnormalities. Front Cardiovasc Med. 2018 Jul 3;5:85. doi: 10.3389/fcvm.2018.00085. eCollection 2018.
- Tsoi M, Tandon K, Zimetbaum PJ, Frishman WH. Conduction Disturbances and Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement: Predictors and Prevention. Cardiol Rev. 2022 Jul-Aug 01;30(4):179-187. doi: 10.1097/CRD.0000000000000398. Epub 2021 Jun 14.
- Kooistra NHM, van Mourik MS, Rodriguez-Olivares R, Maass AH, Nijenhuis VJ, van der Werf R, Ten Berg JM, Kraaijeveld AO, Baan J Jr, Voskuil M, Vis MM, Stella PR. Late onset of new conduction disturbances requiring permanent pacemaker implantation following TAVI. Heart. 2020 Aug;106(16):1244-1251. doi: 10.1136/heartjnl-2019-315967. Epub 2020 Jan 31.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IMPROVE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.